ABUS
NASDAQ · Biotechnology
Arbutus Biopharma Corp
$4.24
-0.13 (-2.97%)
Financial Highlights (FY 2026)
Revenue
7.09M
Net Income
-80,498,287
Gross Margin
—
Profit Margin
-1,133.0%
Rev Growth
-17.5%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 64.9% | 64.9% |
| Operating Margin | -1,236.7% | -1,113.1% | -11.9% | -12.7% |
| Profit Margin | -1,133.0% | -1,076.4% | -11.3% | -11.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 7.09M | 8.60M | 146.67M | 133.60M |
| Gross Profit | — | — | 95.21M | 86.72M |
| Operating Income | -87,741,991 | -95,718,535 | -17,469,791 | -16,985,358 |
| Net Income | -80,498,287 | -87,816,313 | -16,611,843 | -15,300,824 |
| Gross Margin | — | — | 64.9% | 64.9% |
| Operating Margin | -1,236.7% | -1,113.1% | -11.9% | -12.7% |
| Profit Margin | -1,133.0% | -1,076.4% | -11.3% | -11.5% |
| Rev Growth | -17.5% | -17.5% | -8.1% | +23.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 21.36M | 21.36M | 270.84M | 284.74M |
| Total Equity | 430.60M | 430.60M | 467.84M | 533.69M |
| D/E Ratio | 0.05 | 0.05 | 0.58 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -86,268,008 | -99,338,918 | -23,689,130 | -19,063,619 |
| Free Cash Flow | — | — | -19,958,595 | -16,903,048 |